One of The Medical Capital’s most innovative and growing bioscience sectors, regenerative medicine, includes stem cells, cell therapy, tissue engineering, implants and devices used to repair or replace tissue or organ function lost to age, disease, damage, or congenital defects. Talent from The Medical Capital’s world class clinical and research institutions has fueled the development of this sector, with investigators in more than 40 separate facilities producing medical breakthroughs and advancements in regenerative medicine.
Located on the Case Western Reserve University (CWRU) campus, the National Center for Regenerative Medicine (NCRM) is one of The Medical Capital’s most esteemed multi-institutional assets, and is ranked one of the top five stem cell organizations in the country. NCRM, a collaboration among CWRU, Cleveland Clinic, University Hospitals Case Medical Center, Athersys, and The Ohio State University, has attracted more than $400 million in research funding since its founding in 2003.
Alongside institutional advances, companies in The Medical Capital are indeed making significant progress in the research and commercialization of cellular therapies. Abeona Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, was started in 2013 and acquired by PlasmaTech Pharmaceuticals in 2015. PlasmaTech recruited Abeona’s president and CEO, Tim Miller, to be the president and CEO of the newly combined company and it took the Abeona Therapeutics name. Abeona is now publicly traded (NASDAQ: ABEO) and has three gene therapies in clinical trials across multiple countries. Abeona Therapeutics continues to grow and thrive in Cleveland’s Health-tech Corridor.